Brain metastases exploration in metastatic breast cancer treated with Herceptin®: a place for biological tools?;Recherche des métastases cérébrales dans les cancers du sein métastatiques traités par Herceptin® : une place pour la biologie ?

Immuno-Analyse et Biologie Specialisee

Volumn 22, Issue 3, 2007, Pages 151-155

  Pez, E ^a   Gauchez, A S ^a,c   Payan, R ^b   Mousseau, M ^a,c  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Clinique Belledonne   (France)

^c Université Grenoble Alpes   (France)

Author keywords

Brain metastases; Breast cancer; Cerebrospinal fluid; Trastuzumab; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 34248594770     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2007.01.003     Document Type: Article

References (18)

1. Ballabh P., Braun A., and Nedergaard M. The blood-brain barrier: an overview structure, regulation and clinical implications. Neurobiol. Dis. 16 (2004) 1-13
2. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., et al. Central nervous system metastasis in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
3. Bergman I., Barmada M., Griffin J., and Slamon D. Treatment of meningeal breast cancer xenografts in rat using an Anti-P185/her2 antibody. Clin. Cancer Res. 7 (2001) 2050-2056
4. Clayton A.J., Danson S., Jolly S., Ryder W.D., Burt P.A., Stewart A.L., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer 91 (2004) 639-643
5. Combaret V., Audoynaud C., Iacono I., Favrot M.C., Schell M., Bergeron C., et al. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res. 62 (2002) 3646-3648
6. Guepratte S., Pallud D., and Pichon M.F. Dosage des marqueurs tumoraux ACE, CA 15,3, CA 125 et CA 19,9 dans les liquides d'épanchement et le LCR par immunoanalyse en phase homogène. Corrélation avec les résultats cytologiques et les concentrations sériques. IBS 1 (2002) 18-25
7. Huynh G.H., Deen D.F., and Szoka Jr F.C. Barrier to carrier mediated drug and gene delivery to brain tumors. J. Control. Release 110 (2006) 236-259
8. Kemper E.M., Boogerd W., Thuis I., Beijnen J., and Van Tellingen O. Modulation of blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treat. Rev. 30 (2004) 415-423
9. Lai R., Dang C.T., Malkin M.G., and Abrey L.E. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101 (2004) 810-816
10. Li X.P., Meng Z.Q., Guo W.J., and Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J. Gastroenterol. 11 (2005) 3782-3787
11. Lin N., Bellon J.R., and Winer E.P. CNS metastases in breast cancer. J. Clin. Oncol. 22 (2004) 3608-3617
12. Lower E.E., Drosick D.R., Blau R., Brennan L., Danneman W., and Hawley D.K. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin. Breast Cancer 4 (2003) 114-119
13. Pestazolli B.C., and Brignolli S. Trastuzumab in CSF?. J. Clin. Oncol. 18 (2000) 2349-2351
14. Robin I.A., Liu G., Hayes L., and Mehta M. Trastuzumab for breast cancer related carcinomatous meningitis. Clin. Breast Cancer 2 4 (2002) 316
15. Shmueli E., Wigler N., and Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur. J. Cancer 40 (2004) 379-382
16. Tait R.C., Waterworth A., Loncaster J., Horgan K., and Dodwell D. The oligometastatic state in breast cancer: hypothesis or reality. Breast 14 (2005) 87-93
17. Tubiana M., and Koscielny S. Natural history of human cancer and prognostic factor: the example of breast cancer. Bull. Cancer 74 (1987) 43-57
18. Wyld L., Gutteridge E., Pinder S.E., James J.J., Chan S.Y., Cheung K.L., et al. Prognostic factors for patients with hepatic metastasis from breast cancer. Br. J. Cancer 89 (2003) 284-290